<p>VYNE Therapeutics Inc. has entered into an amendment to its agreement with Yarrow Bioscience, Inc. and Yarrow Merger Sub Corp. The amendment allows VYNE to provide certain pre-funded warrants to Yarrow stockholders who, under the exchange ratio, would otherwise exceed a set beneficial ownership limitation. These pre-funded warrants will permit holders to purchase shares of VYNE common stock equal to the excess entitlement. The update also clarifies that the Parent Pre-Closing Dividend may be awarded to holders of VYNE common stock and shares underlying certain outstanding VYNE warrants as of the record date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-008642), on January 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

ATRA

Reuters

SPDR S&P Biotech

Atara Biotherap

iShares US Pharma

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VYNE Therapeutics

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Direxion S&P Biotech Bear 3X

ArrowHead Pharma

Vyne Therapeutics Amends Merger Agreement With Yarrow Bioscience